Insulet Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Ultragenyx Pharmaceutical (RARE)
Insulet Analyst Ratings
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Insulet's Strong Market Position and Financial Health Merit a Buy Rating Despite Legal Challenges
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Insulet Analyst Ratings
Insulet's Strong Financial Performance and Strategic Developments Merit a Buy Rating
Insulet (PODD) Gets a Hold From Stifel Nicolaus
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)
Bank of America Securities Reaffirms Their Buy Rating on Insulet (PODD)
Insulet Analyst Ratings
Insulet (PODD) Gets a Buy From Piper Sandler
Stifel Adjusts Price Target on Insulet to $185 From $208
Insulet's Upbeat Performance and Future Outlook Justify a Buy Rating
Insulet Analyst Ratings
Insulet's Market Dominance and Growth Catalysts Prompt 'Buy' Rating
Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target Is $200
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)